As Bluebird backpedals from Europe, gene therapy players face hurdles – STAT

After Bluebird Bio (BLUE) announced plans this week to end commercial operations in Europe, the move is raising fresh questions about the extent to which selling such pricey treatments is viable for small biotechs in one of the worlds biggest markets.

In explaining the move, the biotech complained that it has become a losing proposition trying to convince European Union member states to make large upfront payments for therapies that can save health care systems much higher costs later. So instead, the company is shifting its focus to the U.S., where it is more likely to get reimbursed at the desired prices.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

The rest is here:
As Bluebird backpedals from Europe, gene therapy players face hurdles - STAT